Zongertinib in Previously Treated <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

John V. Heymach

Gerrina Ruiter

Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam

Myung-Ju Ahn

Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Nicolas Girard

Institut Curie, Institut du Thorax Curie-Montsouris, Paris

Egbert F. Smit

David Planchard

Yi-Long Wu

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

Byoung Chul Cho

Noboru Yamamoto

Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo

Joshua K. Sabari

Division of Medical Oncology, Perlmutter Cancer Center, New York University Langone Health, New York

Yanqiu Zhao

Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

Hai-Yan Tu

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

Kiyotaka Yoh

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Ernest Nadal

Thoracic Tumors Unit, Medical Oncology, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L’Hospitalet de Llobregat, Barcelona

Behbood Sadrolhefazi

Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT

Maren Rohrbacher

Boehringer Ingelheim International, Ingelheim am Rhein, Germany

Ute von Wangenheim

Boehringer Ingelheim Pharma, Biberach an der Riss, Germany

Sabina Eigenbrod-Giese

Boehringer Ingelheim International, Ingelheim am Rhein, Germany

Jon Zugazagoitia

Department of Medical Oncology, 12 de Octubre Hospital, Madrid